KRAS and cancer: We included known missense mutations in six bona fide oncogenes (BRAF, KIT, PIK3CA, KRAS, EGFR, ERRB2), six recently described cancer genes (ESR1, DICER1, MYOD1, IDH1, IDH2, SF3B1) and three bona fide TSGs (TP53, BRCA1, BRCA2) in this study.